Receptor-Dependent Growth Inhibition of Human Pancreatic Cancer by 9-cis Retinoic Acid

被引：6

作者：

Vickers S.M. ^{[1
,2
]}

Sampson L.K. ^{[1
]}

Ying W. ^{[1
]}

Phillips J.O. ^{[1
]}

机构：

[1] Departments of Medicine and Surgery, University of Alabama at Birmingham, Birmingham, AL

[2] University of Alabama at Birmingham, Department of Surgery, Kracke Building, Birmingham

来源：

Journal of Gastrointestinal Surgery | 1997年 / 1卷 / 2期

关键词：

Pancreatic Cancer; Retinoic Acid; Retinoid; Acute Promyelocytic Leukemia; Pancreatic Cancer Cell Line;

D O I：

10.1016/S1091-255X(97)80106-0

中图分类号：

学科分类号：

摘要：

Pancreatic cancer continues to be a lethal disease and ranks as the fifth major cause of cancer death with a 2-year survival rate of only 8%. Although significant progress has been made in the surgical management of this malignancy, there have been only minimal advances in adjuvant therapy. Based on the lack of effective adjuvant or primary therapy for these patients, we tested the effects of various retinoids (all-trans, 9-cis, and 13-cis retinoic acids) on the growth of several human pancreatic cancer cell lines. Four human pancreatic cancer cell lines, designated PANC-1, ASPC, BxPc, and HPAF, were studied. Three types of retinoic acid were added to subconfluent monolayers of the different cancer cell lines over a range of concentrations (1 to 20 μmol/L). Effects on cell growth were determined daily over 96 hours by a cell proliferation assay (MTT). Nuclear receptor (RAR/RXR) transcript and protein were determined by reverse transcription polymerase chain reaction and Western blot analyses. Three (PANC-1, ASPC, and BxPc) pancreatic cancer cell lines responded in a dose-dependent fashion with a significant decrease in cell growth at clinically relevant concentrations of 9-cis retinoic acid (7.5 to 10 μmol/L). All-trans and 13-cis retinoic acid did not affect cell growth in the four pancreatic tumors.

引用

页码：174 / 181

页数：7

共 22 条

[1]

Lillimoe K.D., Current management of pancreatic carcinoma, Ann Surg, 221, pp. 133-148, (1995)

[2]

McGuire G.E., Pitt H.A., Lillimoe K.D., Et al., Reoperative surgery for periampullary adenocarcinoma, Arch Surg, 126, pp. 1205-1212, (1991)

[3]

Crist D.W., Sitzmann J.V., Cameron J.L., Improved hospital morbidity, mortality and survival after the Whipple procedure, Ann Surg, 3, pp. 358-365, (1987)

[4]

Gudjonsson B., Carcinoma of the pancreas: Critical analysis of cost, results of resection and the need for standardized reporting, J Am Coll Surg, 181, pp. 483-503, (1995)

[5]

Pemrick S.M., Lucas D.A., Grippo J.F., The retinoid receptors, Leukemia, 8, SUPPL. 3, (1994)

[6]

Connie M., Agadir A., Degos L., Chomienne C., Retinoids and differentiation treatment: A strategy for treatment in cancer, Anticancer Res, 14, pp. 2339-2346, (1994)

[7]

Butler W.B., Fontant J.A., Responses to retinoic acid of tamoxifen-sensitive and resistant sublines of human breast cancer cell line MCF-7, Cancer Res, 52, pp. 6164-6167, (1992)

[8]

Eisenhauer E.A., Lippman S.M., Kavanagh J.J., Et al., Combination 13-cis retinoic acid and interferon α 2 a in the therapy of solid tumors, Leukemia, 8, pp. 1622-1625, (1994)

[9]

Adamson P.C., Clinical and pharmacokinetic studies of all-trans retinoic acid in pediatric patients with cancer, Leukemia, 8, pp. 1813-1816, (1994)

[10]

Houle B., Rochette-Egly C., Bradley W.E.C., Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells, Proc Natl Acad Sci USA, 90, pp. 985-989, (1993)

← 1 2 3 →